⌘K
t
Tristel plc issued and allotted 5,000 new ordinary shares following the exercise of options by employees. Application has been made for these 5,000 new shares, along with a previously announced 15,000 new shares, to be admitted to AIM trading, effective 16 October 2025. After admission, the total number of ordinary shares and voting rights in issue for Tristel plc will be 47,745,043.
| Date | 13 Oct 2025 |
| Time | 12:00:00 |
| Category | Capital structure |
| ID | 1016D |
Tristel plc
("Tristel" or the "Company")
Exercise of Share Options and Total Voting Rights
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a further 5,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following another exercise of options by employees of the Company.
Application has been made to the London Stock Exchange for the additional 5,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 16 October 2025, together with the 15,000 new ordinary shares to be admitted to trading on AIM pursuant to the employee exercise of options announced on 9 October.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be 47,745,043 and the total number of voting rights will therefore be 47,745,043. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
|
Tristel plc |
Via Walbrook PR |
|||
|
Matt Sassone, Chief Executive Officer |
||||
|
Anna Wasyl, Chief Financial Officer |
|
|||
|
|
|
|||
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
|||
|
Paul McManus / Lianne Applegarth / Anna Dunphy |
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001 |
|||
|
|
|
|||
|
Cavendish Capital Markets Ltd |
Tel: 020 7220 0500 |
|||
|
Geoff Nash / Callum Davidson / Trisyia Jamaludin (Corporate Finance) |
|
|||
|
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales) |
|
|||
About Tristel plc
Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.
The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product range please visit: https://tristel.com